» Articles » PMID: 14662251

N-terminal Pro-brain Natriuretic Peptide in Relation to Inflammation, Myocardial Necrosis, and the Effect of an Invasive Strategy in Unstable Coronary Artery Disease

Overview
Date 2003 Dec 10
PMID 14662251
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: We sought to examine whether measurements of N-terminal pro-brain natriuretic peptide (NT-proBNP), in addition to cardiac troponin T (cTnT) and interleukin-6 (IL-6), improve the ability to identify high-risk patients who benefit from an early invasive strategy.

Background: Biochemical indicators of cardiac performance (e.g., NT-proBNP), inflammation (e.g., IL-6), and myocardial damage (e.g., cTnT) predict mortality in unstable coronary artery disease (UCAD) (i.e., unstable angina or non-ST-segment elevation myocardial infarction [MI]). In these patients, an early invasive treatment strategy improves the outcome.

Methods: Levels of NT-proBNP, cTnT, and IL-6 were measured in 2,019 patients with UCAD randomized to an invasive or non-invasive strategy in the FRagmin and fast revascularization during InStability in Coronary artery disease (FRISC-II) trial. Patients were followed up for two years to determine death and MI.

Results: Patients in the third NT-proBNP tertile had a 4.1-fold (95% confidence interval [CI] 2.4 to 7.2) and 3.5-fold (95% CI 1.8 to 6.8) increased mortality in the non-invasive and invasive groups, respectively. An increased NT-proBNP level was independently associated with mortality. In patients with increased levels of both NT-proBNP and IL-6, an early invasive strategy reduced mortality by 7.3% (risk ratio 0.46, 95% CI 0.21 to 1.00). In patients with lower NT-proBNP or IL-6 levels, the mortality was not reduced. Only elevated cTnT was independently associated with future MI and a reduction of MI by means of an invasive strategy.

Conclusions: N-terminal proBNP is independently associated with mortality. The combination of NT-proBNP and IL-6 seems to be a useful tool in the identification of patients with a definite survival benefit from an early invasive strategy. Only cTnT is independently associated with future MI and a reduction of MI by an invasive strategy.

Citing Articles

Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome.

Katsioupa M, Kourampi I, Oikonomou E, Tsigkou V, Theofilis P, Charalambous G Life (Basel). 2023; 13(10).

PMID: 37895374 PMC: 10608753. DOI: 10.3390/life13101992.


The joint association of diabetes status and NT-ProBNP with adverse cardiac outcomes in patients with non-ST-segment elevation acute coronary syndrome: a prospective cohort study.

Wang M, Su W, Chen H, Li H Cardiovasc Diabetol. 2023; 22(1):46.

PMID: 36871021 PMC: 9985841. DOI: 10.1186/s12933-023-01771-1.


Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins.

Eggers K, Lindahl B Curr Cardiol Rep. 2017; 19(4):29.

PMID: 28315120 PMC: 5357245. DOI: 10.1007/s11886-017-0840-3.


B-type natriuretic peptide-guided treatment for heart failure.

McLellan J, Heneghan C, Perera R, Clements A, Glasziou P, Kearley K Cochrane Database Syst Rev. 2017; 12:CD008966.

PMID: 28102899 PMC: 5449577. DOI: 10.1002/14651858.CD008966.pub2.


Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era.

Fanning J, Nyong J, Scott I, Aroney C, Walters D Cochrane Database Syst Rev. 2016; (5):CD004815.

PMID: 27226069 PMC: 8568369. DOI: 10.1002/14651858.CD004815.pub4.